Volume 27, Number 11—November 2021
Dispatch
Mutations Associated with SARS-CoV-2 Variants of Concern, Benin, Early 2021
Table 2
Sample no. | 251307 | 314235 | 251455 | 312541 |
---|---|---|---|---|
Lineage |
B.1 |
B.1.1.7 |
A.27 |
B.1.214.2 |
Mutations |
Q52R, Del HV69/70, Del Y144, E484K, D614G, Q677H, F888L |
Del HV69/70, Del Y144, F490S, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H |
L18F, L452R, N501Y, A653V, H655Y, D796Y, G1219V |
Ins R214TDR, Q414K, D614G, T716I |
Patient-derived samples | ||||
Mean titer (95% CI) | 23 (–12.4 to 58.4) | 35.5 (–12 to 83) | 65.6 (–46.6 to 177.7) | 148.9 (–86.59 to 384.3) |
No. (%) neutralized | 3/6 (50) | 5/6 (83.3) | 4/6 (66.7) | 6/6 (100) |
Titer difference† |
52.2 (1.5-fold) |
39.7 |
9.7 |
–73.6‡ |
Vaccinee-derived samples | ||||
Mean titer (95% CI) | 180.5 (102.8–258.1) | 156.2 (33.6–278.7) | 293.7 (57.1–530.2) | 698.3 (446.8–949.9) |
No. (%) neutralized | 7/7 (100) | 7/7 (100) | 7/7 (100) | 7/7 (100) |
Titer difference† | 136.7 | 161 | 23.5 | –381.1‡ |
*PRNT50, 50% plaque reduction neutralization test. †Compared to variant B.1.153. ‡Lower titers against the early isolate compared with this Benin-derived isolate.
1These first authors contributed equally to this article.
Page created: August 09, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.